Given that AhR activation mediates cardiotoxicity and vascular damage through procoagulant and prooxidant phenotypes [30], the effects of KYN metabolite accumulation on the cardiovascular system in CKD patients can in part be explained by AhR activity modulation. The gene discussed is AHR; the disease is chronic kidney disease.